Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, Sumi H, Hizukuri Y, Hong Y, Patel P, Seki T, Duan T, Lesegretain A, Andreeff M. DiNardo CD, et al. Among authors: kumar p. Cancer Med. 2024 Jul;13(14):e70028. doi: 10.1002/cam4.70028. Cancer Med. 2024. PMID: 39030997 Free PMC article. Clinical Trial.
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru VG, Xu F, Doebele RC, Hong DS. Gounder MM, et al. Among authors: kumar p. J Clin Oncol. 2023 Mar 20;41(9):1714-1724. doi: 10.1200/JCO.22.01285. Epub 2023 Jan 20. J Clin Oncol. 2023. PMID: 36669146 Free PMC article. Clinical Trial.
A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.
George S, Heinrich MC, Somaiah N, Oppelt P, McLeod R, Nishioka S, Kundu MG, Qian X, Kumar P, Laadem A, Lau Y, Tran BP, Fallon M, Dosunmu O, Shi J, Naito Y. George S, et al. Among authors: kumar p. Clin Cancer Res. 2023 Sep 15;29(18):3659-3667. doi: 10.1158/1078-0432.CCR-23-0640. Clin Cancer Res. 2023. PMID: 37363962 Free PMC article.
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.
Yokota T, Bendell J, LoRusso P, Tsushima T, Desai V, Kenmotsu H, Watanabe J, Ono A, Murugesan B, Silva J, Naito T, Greenberg J, Kumar P, Wang Y, Jikoh T, Shiga R, Hyman DM, Ho AL, Spriggs DR, Schwartz GK, Gounder MM. Yokota T, et al. Among authors: kumar p. Br J Cancer. 2018 Jun;118(12):1571-1579. doi: 10.1038/s41416-018-0102-1. Epub 2018 May 24. Br J Cancer. 2018. PMID: 29795308 Free PMC article. Clinical Trial.
Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.
Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, Kumar P, Gabrilovich DI. Dominguez GA, et al. Among authors: kumar p. Clin Cancer Res. 2017 Jun 15;23(12):2942-2950. doi: 10.1158/1078-0432.CCR-16-1784. Epub 2016 Dec 13. Clin Cancer Res. 2017. PMID: 27965309 Free PMC article. Clinical Trial.
Mechanical Circulatory Support for Massive Pulmonary Embolism.
Abdulaziz S MBBS, Kakar V, Kumar PG, Hassan IF, Combes A, Brodie D, Barrett NA, Tan J, Al Ali SF. Abdulaziz S MBBS, et al. Among authors: kumar pg. J Am Heart Assoc. 2024 Dec 24:eJAHA2024036101T. doi: 10.1161/JAHA.124.036101. Online ahead of print. J Am Heart Assoc. 2024. PMID: 39719427 Free article. Review.
14,710 results
You have reached the last available page of results. Please see the User Guide for more information.